Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors

Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-peptide based drugs targeting the proteasome’s 19S...

Descripción completa

Detalles Bibliográficos
Autores principales: Anchoori, Ravi K., George, Logan, Tseng, Ssu-Hsueh, Lam, Brandon, Polkampally, Srinidhi, Amiano, Anjali D., Foran, Palmer, Tsingine, Hannah, Samanapally, Harideep, Carrizo Velasquez, Fernanda, Das, Samarjit, Xing, Deyin, Bin Salam, Ahmad, Karanam, Balasubramanyam, Hung, Chien-Fu, Roden, Richard B. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432795/
https://www.ncbi.nlm.nih.gov/pubmed/34506530
http://dx.doi.org/10.1371/journal.pone.0256937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432795/
https://www.ncbi.nlm.nih.gov/pubmed/34506530
http://dx.doi.org/10.1371/journal.pone.0256937

Ejemplares similares